89bio, Inc.
ETNB
$9.03
-$0.39-4.14%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 31.43% | 26.62% | 36.74% | 32.08% | 38.20% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 143.47% | 124.10% | 154.40% | 124.48% | 55.43% |
Operating Income | -143.47% | -124.10% | -154.40% | -124.48% | -55.43% |
Income Before Tax | -163.24% | -139.61% | -164.88% | -124.95% | -43.75% |
Income Tax Expenses | -67.03% | -81.53% | -82.10% | 26,787.50% | 22,666.67% |
Earnings from Continuing Operations | -157.83% | -134.30% | -158.16% | -128.33% | -47.18% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -157.83% | -134.30% | -158.16% | -128.33% | -47.18% |
EBIT | -143.47% | -124.10% | -154.40% | -124.48% | -55.43% |
EBITDA | -143.51% | -124.14% | -154.45% | -124.53% | -55.46% |
EPS Basic | -82.76% | -68.13% | -70.46% | -45.58% | 6.56% |
Normalized Basic EPS | -83.53% | -68.97% | -72.87% | -43.15% | 7.92% |
EPS Diluted | -82.76% | -68.13% | -70.46% | -45.58% | 6.56% |
Normalized Diluted EPS | -83.53% | -68.97% | -72.87% | -43.15% | 7.92% |
Average Basic Shares Outstanding | 49.49% | 43.49% | 47.26% | 50.70% | 56.51% |
Average Diluted Shares Outstanding | 49.49% | 43.49% | 47.26% | 50.70% | 56.51% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |